Judah Frommer, an analyst from Morgan Stanley, maintained the Buy rating on Kymera Therapeutics. The associated price target remains the same with $70.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Judah Frommer has given his Buy rating due to a combination of factors including the promising preclinical data presented by Kymera Therapeutics for their IRF5 degrader, KT-579. The data showcased at the ACR 2025 highlighted significant reductions in anti-dsDNA antibodies in lupus models, indicating a stronger efficacy compared to other treatments.
Additionally, the data demonstrated KT-579’s ability to decrease pathogenic autoantibodies and inhibit key interferon genes, which are crucial in the progression of autoimmune diseases. With a Phase 1 study expected to commence in early 2026, these developments underscore the potential of KT-579 in treating diseases driven by IRF5 dysregulation, supporting Frommer’s optimistic outlook on the stock.
In another report released on October 24, Citi also assigned a Buy rating to the stock with a $80.00 price target.